SCHEMBL12065615

SCHEMBL12065615

Fc1ccc2[nH]c(C(OCC(F)(F)F)c3ccc(OC(F)(F)F)cc3)nc2c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 1/20 0.38
▸ TRPA1 O75762 2/20 0.37
▸ ALPL P05186 1/20 0.34
▸ ALPI P09923 1/20 0.34
▸ ALPG P10696 1/20 0.34
▸ PRCP P42785 2/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.33
▸ MLKL Q8NB16 1/20 0.33
▸ GPR139 Q6DWJ6 1/20 0.33
▸ TRPV1 Q8NER1 2/20 0.33
▸ DPP4 P27487 1/20 0.32
▸ NR3C2 P08235 1/20 0.32
▸ PDE2A O00408 3/20 0.32
▸ CBFB Q13951 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770500 0.89 MLKL (0.38) SCN10AALPLALPIALPGPRCP
SCHEMBL12065255 0.89 SCN10A (0.40) SCN10ATRPA1ALPLALPIALPG
SCHEMBL12066063 0.88 SCN10A (0.38) SCN10ATRPA1ALPLALPIALPG
SCHEMBL12065641 0.87 ALPL (0.38) SCN10ATRPA1ALPLALPIALPG
SCHEMBL12065659 0.87 SCN10A (0.39) SCN10ATRPA1ALPLALPIALPG
SCHEMBL12065633 0.86 SCN10A (0.41) SCN10ATRPA1TRPV4MLKLGPR139
SCHEMBL14762782 0.86 SCN10A (0.43) SCN10ATRPA1ALPLALPIALPG
SCHEMBL12066547 0.85 SCN10A (0.43) SCN10ATRPA1MLKLNR3C2PDE2A
SCHEMBL14762836 0.85 MLKL (0.48) SCN10ATRPA1ALPLALPIALPG
Oxalic Acid SCHEMBL14762710 0.84 PDE2A (0.38) SCN10AMLKLGPR139PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A SCN10A 85/4885TRPA1 58/4885ALPL 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback